Trial Profile

Impact of gene polymorphism on the pharmacokinetics and the clinical response in patients with hepatocellular carcinoma using lenvatinib

Status: Discontinued

Phase of Trial: Phase IV

Latest Information Update: 11 Jul 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lenvatinib (Primary)
Indications Liver cancer
Focus Pharmacogenomic; Therapeutic Use

Most Recent Events

08 Jul 2022 Planned End Date changed from 31 Mar 2023 to 31 Jul 2021.
08 Jul 2022 Status changed from recruiting to discontinued.
01 Jan 2022 Results of effects of genetic polymorphisms on the pharmacokinetics and pharmacodynamics of lenvatinib (n=48) published in the Journal of Pharmacological Sciences

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com